List of Excipients in Branded Drug ABILIFY MYCITE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Otsuka America Pharmaceutical Inc	ABILIFY MYCITE	aripiprazole	59148-029	ALUMINUM
Otsuka America Pharmaceutical Inc	ABILIFY MYCITE	aripiprazole	59148-029	CELLULOSE, MICROCRYSTALLINE
Otsuka America Pharmaceutical Inc	ABILIFY MYCITE	aripiprazole	59148-029	CUPROUS CHLORIDE
Otsuka America Pharmaceutical Inc	ABILIFY MYCITE	aripiprazole	59148-029	ETHYLCELLULOSE
Otsuka America Pharmaceutical Inc	ABILIFY MYCITE	aripiprazole	59148-029	FD&C BLUE NO. 2
Otsuka America Pharmaceutical Inc	ABILIFY MYCITE	aripiprazole	59148-029	FERRIC OXIDE YELLOW
Otsuka America Pharmaceutical Inc	ABILIFY MYCITE	aripiprazole	59148-029	GOLD

Abilify MyCite Excipient Strategy and Commercial Opportunities

Last updated: September 26, 2026

Abilify MyCite combines aripiprazole with an ingestible event marker, wearable sensor patch, mobile application, and digital health platform. Its commercial differentiation does not come from a novel excipient system alone. The value is in integrating a conventional immediate-release aripiprazole tablet with a drug-device combination that records medication ingestion events. The main excipient opportunities are therefore in tablet robustness, sensor compatibility, manufacturing yield, patient tolerability, and future digital formulations. [1]

What is Abilify MyCite and how does its formulation work?

Abilify MyCite is an oral tablet containing aripiprazole and an ingestible sensor. The FDA approved it in November 2017 for adults with schizophrenia, adults with bipolar I disorder, and adults with major depressive disorder as an adjunct to antidepressants. [1]

The system includes four components:

Component	Function	Commercial relevance
Aripiprazole tablet	Delivers the active pharmaceutical ingredient	Uses a conventional immediate-release oral dosage form
Ingestible event marker	Activates after exposure to gastric fluid	Differentiates MyCite from ordinary aripiprazole tablets
MyCite patch	Detects the marker signal and records a time-stamped event	Creates recurring device and replacement-patch demand
Smartphone application and portal	Transmits and displays ingestion data	Supports adherence monitoring and clinical workflows

The product is designed to record that the tablet has been ingested. It does not prove complete absorption, therapeutic response, or adherence to all prescribed doses. The FDA label also states that the system is not indicated to improve adherence. [1]

What excipients are used in Abilify MyCite?

The FDA prescribing information identifies conventional tablet excipients, including lactose monohydrate, microcrystalline cellulose, corn starch, hydroxypropyl cellulose, and magnesium stearate. [1]

These materials perform familiar functions:

Excipient	Likely formulation role	Strategic importance
Lactose monohydrate	Diluent and bulk-forming agent	Supports tablet mass and manufacturability
Microcrystalline cellulose	Diluent and dry-binder	Improves compaction and mechanical strength
Corn starch	Disintegrant and filler	Supports rapid tablet breakup
Hydroxypropyl cellulose	Binder	Controls granule and tablet integrity
Magnesium stearate	Lubricant	Reduces tooling friction during compression

The excipient system is intentionally conventional. Immediate-release aripiprazole does not require a complex controlled-release matrix, lipid system, amorphous dispersion, or solubilizing technology. The key formulation constraint is compatibility with the ingestible sensor and with the manufacturing process used to embed or incorporate the sensor into the tablet.

The ingestible event marker is not a conventional excipient. It is an electronic component that contains materials including copper, magnesium, and silicon and is designed to activate in the presence of gastric fluid. [1] Treating the sensor as an excipient would obscure the regulatory and manufacturing issues that distinguish MyCite from standard aripiprazole tablets.

How does the excipient strategy differ from generic aripiprazole?

Generic aripiprazole tablets use broadly conventional excipient systems and compete primarily on bioequivalence, manufacturing cost, supply reliability, and dosage-form presentation. MyCite adds a device integration requirement.

Attribute	Generic aripiprazole	Abilify MyCite
Active ingredient	Aripiprazole	Aripiprazole
Core dosage form	Immediate-release tablet	Immediate-release tablet with ingestible marker
Sensor	None	Ingestible event marker and wearable patch
Excipient complexity	Conventional	Conventional tablet excipients with sensor-compatibility constraints
Regulatory pathway	Abbreviated application, subject to product-specific requirements	Drug-device combination application
Primary value proposition	Low-cost drug delivery	Medication-event monitoring
Main manufacturing risk	Content uniformity and tablet quality	Tablet quality plus sensor placement, activation, and device integration
Substitution risk	High after generic entry	Lower for the complete digital system, but high for aripiprazole alone

The principal formulation challenge is not achieving a new release profile. It is preserving dose uniformity, disintegration, mechanical integrity, and sensor performance after the electronic marker is introduced into the product.

What excipient properties matter most for MyCite manufacturing?

Tablet strength and sensor survivability

The tablet must withstand compression, coating or finishing operations, packaging, transport, and swallowing. Excessive compression force can damage or deform the sensor. Insufficient compression can produce friability, chipping, or marker displacement.

Microcrystalline cellulose and hydroxypropyl cellulose can support mechanical strength, but their concentrations must be balanced against disintegration performance. A robust design space would evaluate:

• Compression force and dwell time
• Sensor location within the tablet
• Tablet thickness and tensile strength
• Friability after sensor incorporation
• Disintegration time after compression
• Marker activation after exposure to gastric fluid
• Signal detection through the body and wearable patch

Lubrication control

Magnesium stearate is commercially attractive because it is widely available and effective at low concentrations. Excessive lubrication can reduce tablet hardness, slow wetting, and impair dissolution. In a sensor-containing tablet, over-lubrication can also affect powder flow and sensor positioning.

Manufacturers may evaluate alternative lubricants or tighter blending controls, but any change must preserve the approved product’s dissolution, content uniformity, and device performance.

Moisture management

Moisture can affect starch, cellulose-based excipients, aripiprazole stability, and electronic marker performance. Packaging selection is therefore a commercial opportunity. High-barrier blister systems, desiccant strategies, and controlled-humidity manufacturing can reduce stability risk.

Excipient suppliers with strong control of particle-size distribution, moisture content, and batch-to-batch functionality have an advantage in this type of product. The value lies in process consistency rather than in a proprietary ingredient claim.

Disintegration and gastric activation

The tablet must disintegrate and expose the marker after ingestion. A formulation that is too hydrophobic, too highly compressed, or overly lubricated could delay marker activation. Corn starch, microcrystalline cellulose, and the binder-lubricant balance are relevant to this performance requirement.

A formulation change that leaves aripiprazole dissolution within specification could still create a product problem if it changes the timing or reliability of the ingestion signal.

What commercial opportunities exist for excipient suppliers?

Functional excipient supply

The most immediate opportunity is supply of high-consistency grades of:

• Microcrystalline cellulose
• Lactose monohydrate
• Corn starch
• Hydroxypropyl cellulose
• Magnesium stearate

Suppliers can differentiate through low-metal grades, controlled moisture, narrow particle-size distributions, improved flow, and validated performance in direct compression or dry granulation.

Sensor-compatible formulation platforms

A larger opportunity is a formulation platform that supports electronic-marker incorporation without creating new dissolution or content-uniformity problems. Potential technologies include:

• Direct-compression blends with lower compaction stress
• Low-moisture granulation systems
• Co-process excipients that reduce lubricant demand
• High-strength, rapidly disintegrating tablet matrices
• Protective excipient layers around the ingestible marker
• Multiparticulate systems that separate the sensor from the main drug load

Any platform must preserve the sensor’s gastric-fluid activation and maintain the approved aripiprazole exposure profile.

Contract development and manufacturing

CDMOs can offer integrated services covering:

1. Excipient screening
2. Sensor-placement studies
3. Tablet compression and inspection
4. Marker activation testing
5. Dissolution and stability testing
6. Packaging qualification
7. Drug-device quality-system integration

This is more defensible than selling a commodity excipient because it combines formulation know-how with device manufacturing controls.

Future digital medicines

The MyCite architecture could be adapted to other oral medicines where ingestion documentation has clinical or economic value. Candidate categories include antipsychotics, tuberculosis medicines, immunosuppressants, opioid-use-disorder therapies, and selected cardiovascular drugs.

The opportunity is strongest when missed doses have measurable clinical or financial consequences and when care teams can act on the data. It is weaker when adherence monitoring adds cost without changing treatment decisions.

What FDA regulatory issues affect commercial development?

Abilify MyCite is regulated as a drug-device combination product. FDA review therefore extends beyond conventional tablet quality. Developers must address:

• Drug substance and drug product quality
• Sensor identity and performance
• Marker activation and detection
• Patch reliability
• Software and data transmission
• Human factors
• Cybersecurity and privacy controls
• Device component manufacturing
• Complaint handling and post-market surveillance

An excipient change can become more complex if it affects sensor activation, ingestion-event detection, dissolution, or software-generated medication records. A change that would ordinarily qualify as a routine pharmaceutical manufacturing change may require broader combination-product assessment.

The FDA label also warns that the system may fail to detect ingestion and that the patch or application may not function as intended. [1] Those limitations affect commercial positioning: the product is a monitoring system, not a guaranteed adherence solution.

What is the exclusivity and patent position of Abilify MyCite?

Aripiprazole itself has lost ordinary small-molecule exclusivity, and generic aripiprazole products are widely available. The commercial protection for MyCite therefore depends more heavily on the integrated product architecture than on the active ingredient.

Relevant protection categories include:

• Digital medicine system patents
• Ingestible sensor patents
• Sensor activation and signal-detection methods
• Patch and wearable-device patents
• Data transmission and medication-event recording
• Tablet integration and manufacturing methods
• Method-of-use claims directed to adherence monitoring
• Branding and regulatory exclusivities associated with the approved combination product

Public FDA approval does not mean that all relevant patents are listed in the Orange Book. Device and software patents may sit outside ordinary drug patent listings. The practical competitive barrier is the combination of intellectual property, manufacturing know-how, clinical validation, regulatory history, and access to the digital platform.

A generic aripiprazole manufacturer could market the active drug without reproducing MyCite. A competing digital aripiprazole product would face a more complex pathway because it would need to establish both pharmaceutical equivalence or clinical appropriateness and reliable performance of the device system.

Which companies are positioned to challenge or extend the platform?

The relevant competitive groups are broader than traditional generic-drug companies.

Generic aripiprazole manufacturers

Companies such as Teva, Sandoz, Alembic, Lupin, and other approved generic manufacturers compete with oral aripiprazole products. Their products can erode aripiprazole pricing but do not automatically replicate the MyCite system.

Digital medicine developers

Digital therapeutics and medication-adherence companies could compete through:

• Smart pill bottles
• In-home medication sensors
• Electronic blister packs
• Pharmacy-administered adherence programs
• Remote psychiatric monitoring
• Smartphone-based patient-reported adherence systems

These approaches may be cheaper than an ingestible sensor but provide less direct evidence of ingestion.

Large pharmaceutical companies

Drug manufacturers with long-acting injectable antipsychotics have an alternative adherence strategy. Long-acting products such as aripiprazole monohydrate and aripiprazole lauroxil avoid daily oral dosing and may compete with MyCite in patients where adherence is the primary concern.

How does MyCite compare with long-acting aripiprazole products?

Issue	Abilify MyCite	Long-acting aripiprazole
Administration	Daily oral tablet	Periodic injection
Adherence evidence	Records ingestion events when system functions	Confirms administration by healthcare professional
Patient burden	Daily dosing plus patch and smartphone use	Clinic visits and injection
Excipient opportunity	Tablet and sensor compatibility	Injectable suspension or depot formulation
Manufacturing complexity	Drug-device integration	Sterile manufacturing and depot performance
Commercial buyer	Patient, prescriber, payer, health system	Prescriber, clinic, payer
Main limitation	Sensor, patch, connectivity, and workflow failures	Injection burden and scheduled visits

MyCite has a distinct opportunity in patients who prefer oral treatment but require objective medication-event data. Long-acting injectables have a stronger adherence record when the patient attends scheduled administration.

What generic launch risks exist?

Generic entry risk is high for conventional aripiprazole tablets and lower for the complete MyCite system. The risks divide into two markets:

1. Aripiprazole price erosion from ordinary generic tablets.
2. Competition against MyCite from alternative adherence technologies and long-acting injectables.

A generic manufacturer does not need to reproduce the patch and software to capture aripiprazole volume. This creates a two-tier market in which the active ingredient becomes commoditized while the digital system must justify an added price through measurable clinical or operational value.

Potential launch scenarios include:

Scenario	Effect
Generic oral aripiprazole expands	Reduces price of the underlying active drug
Payers reimburse digital monitoring selectively	Preserves premium opportunity in high-risk populations
Health systems adopt remote adherence workflows	Supports institutional demand
Digital sensor reliability remains inconsistent	Limits prescriber uptake
Long-acting injectables gain preference	Narrows the target population
New sensor-enabled products enter	Increases platform and patent pressure

How strong is the commercial patent estate?

The commercial strength of MyCite is likely greater than the strength of a conventional formulation patent but lower than the strength of a product protected by a single indispensable active-ingredient patent.

Its defensibility rests on five factors:

• Integrated drug-device regulatory status
• Sensor and patch technology
• Data platform and workflow integration
• Manufacturing expertise
• Clinical and payer evidence

The excipient component alone is unlikely to create a durable barrier. Conventional excipients are generally difficult to protect broadly unless linked to a specific sensor-integration process, performance limitation, or manufacturing step.

What are the highest-value commercial opportunities?

The most credible opportunities are:

1. High-functionality excipient supply for sensor-containing tablets.
2. CDMO services for drug-device combination products.
3. Packaging and stability systems that protect both tablet and electronics.
4. Digital adherence programs for psychiatry and specialty care.
5. Licensing of ingestible-sensor technology to other oral medicines.
6. Health-economic studies showing reduced hospitalization, relapse, or treatment failure.
7. Companion services for prescriber dashboards and patient support.
8. Reformulation of other drugs where objective ingestion data has clinical value.

The strongest business case will come from demonstrating that medication-event data changes treatment decisions and reduces total healthcare cost. Excipient innovation can improve manufacturability and reliability, but it is unlikely to create the principal revenue pool.

Key Takeaways

• Abilify MyCite uses a conventional immediate-release aripiprazole tablet with an ingestible electronic marker.
• Public labeling identifies lactose monohydrate, microcrystalline cellulose, corn starch, hydroxypropyl cellulose, and magnesium stearate among the inactive ingredients. [1]
• The main formulation challenge is sensor compatibility, not controlled release.
• Excipient suppliers can compete through consistency, moisture control, low-metal grades, and sensor-compatible processing.
• The core commercial moat is the integrated drug-device system, not the excipient blend.
• Generic aripiprazole creates substantial price pressure on the active-drug component.
• Digital monitoring, specialty psychiatry workflows, CDMO services, and platform licensing are the largest adjacent opportunities.
• Long-acting aripiprazole products are the most important clinical and commercial alternative for adherence management.
• Patent value is likely concentrated in sensor, device, software, manufacturing, and method-of-use claims rather than in ordinary excipient claims.

FAQs About Abilify MyCite Excipient and Commercial Strategy

Does Abilify MyCite use a novel excipient?

No. The FDA label identifies conventional pharmaceutical excipients. The product’s novelty is the ingestible event marker and connected monitoring system, not a new inactive ingredient. [1]

Can generic aripiprazole replace Abilify MyCite?

Generic aripiprazole can replace the active drug for patients who do not require the digital monitoring system. It does not reproduce the ingestible sensor, wearable patch, software, or medication-event data.

Is the MyCite sensor an excipient?

No. It is an electronic ingestible device component. Its function is to transmit an ingestion signal after activation by gastric fluid.

Which excipient is most important for MyCite tablet performance?

No single excipient controls the entire product. The balance among microcrystalline cellulose, corn starch, hydroxypropyl cellulose, lactose, and magnesium stearate affects strength, disintegration, lubrication, dissolution, and sensor activation.

Can the MyCite platform be licensed to other drugs?

Potentially. The platform could be adapted to other oral medicines, but each product would require drug-specific formulation development, device validation, regulatory review, manufacturing controls, and clinical justification.

References

1. U.S. Food and Drug Administration. (2017). Abilify MyCite (aripiprazole tablets with sensor): Prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207946s000lbl.pdf

2. U.S. Food and Drug Administration. (2017, November 13). FDA approves pill with sensor that digitally tracks if patients have ingested their medication. FDA. https://www.fda.gov/news-events/press-announcements/fda-approves-pill-sensor-digitally-tracks-if-patients-have-ingested-their-medication

3. U.S. Food and Drug Administration. (2020). Drug development and drug interactions: Table of substrates, inhibitors and inducers. FDA. https://www.fda.gov

4. U.S. Food and Drug Administration. (2022). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/ index.cfm